Finally, the role of monotherapy with mTOR inhibitors has become less popular in advanced RCC and should be reserved for patients with molecular genotypes that would predict response to mTOR-based therapy (i.e. TSC1/2 mutations). This evidence concerns the gene TSC1 and renal cell carcinoma.